Navigation Links
Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
Date:11/28/2007

Advanced Bio-Surfaces releases data on minimally invasive alternative to

total knee replacement

MINNEAPOLIS, Nov. 28 /PRNewswire/ -- Advanced Bio-Surfaces, Inc. (ABS), announced today the availability of OrthoGlide Medial Knee Implant initial clinical data.

Data representing the first complete year of enrollment in the OrthoGlide clinical study was presented on November 10th, 2007 at the American College of Rheumatology's annual meeting in Boston, MA. The data was presented by William Arnold, M.D., Medical Director for ABS. "The OrthoGlide prospective clinical study has enrolled 92 patients with osteoarthritis of the medial compartment that met the inclusion criteria," said Dr. Arnold. "These patients would have been candidates for an invasive Total Knee Replacement (TKR) procedure."

A summary of the data includes 92 patients implanted at 6 approved sites in the United States. Fourteen of the enrolled patients have surpassed the one year implant anniversary. The demographics of the study group include an average age of 60 years, 52% male / 48% female and WOMAC Pain scores which improve from 35 pre-operatively to 72 at 6 months and 74 at one year post- operative. The most serious adverse event reported was the need to convert patients to either a unicompartmental knee or TKR. Nine OrthoGlide patients enrolled (10.2%) were converted, which is comparable to the 9% unicompartmental knee conversion rate at two years post-operative. Also important is the fact that only one patient out of 350 total implants (includes study and non-study patients) experienced a dislocation.

Dr. Arnold summarized the data by saying, "The pain relief experienced by the patients enrolled in this study, along with the return of knee function at one year is similar to TKR results but with a much less invasive procedure."

About Advanced Bio-Surfaces, Inc.

ABS is a privately held company dedicated to the development of innovative joint restoration products. The company's first product, the OrthoGlide Medial Knee Implant, is intended for the treatment of patients with moderate osteoarthritis of the medial compartment. It is securely implanted without bone cutting or rigid fixation, is expected to provide a more rapid recovery than TKR, a shorter hospital stay and no rehabilitation. The company received 510(k) clearance to market in February 2006 and 350 implants have been completed. For additional information contact ABS at 952.912.5400 or visit the website at http://www.advbiosurf.com.


'/>"/>
SOURCE Advanced Bio-Surfaces, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):